Treat to target in axial spondyloarthritis: from its concept to its implementation

M Dougados - Journal of Autoimmunity, 2020 - Elsevier
Treat to target is defined by a process defining a level of a relevant outcome of the disease
to be reached in order to prevent subsequent disability The benefit of a Treat to Target …

Association of HLA-B27 with ankylosing spondylitis and clinical features of the HLA-B27-associated ankylosing spondylitis: a meta-analysis

H Lin, YZ Gong - Rheumatology International, 2017 - Springer
Many studies have estimated the correlation between HLA-B27 polymorphisms and
ankylosing spondylitis (AS). However, the results were controversial. Therefore, we …

Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis

A Ciurea, A Scherer, U Weber, P Exer… - Annals of the …, 2016 - ard.bmj.com
Objectives To investigate the impact of smoking on the response to treatment with a first
tumour necrosis factor inhibitor (TNFi) in patients with axial spondyloarthritis (axSpA) in a …

Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice

T Rusman, S Ten Wolde, SM Euser… - … journal of rheumatic …, 2018 - Wiley Online Library
Aim To assess gender differences in ankylosing spondylitis (AS) patients in relation to tumor
necrosis factor alpha inhibitor (TNF i) drug survival and occurrence of adverse events in …

High prevalence of hidradenitis suppurativa symptoms in axial spondyloarthritis patients: A possible new extra-articular manifestation

A Rondags, S Arends, FR Wink, B Horváth… - Seminars in arthritis and …, 2019 - Elsevier
Abstract Background Spondyloarthritis (SpA), a chronic inflammatory, rheumatic disease,
and hidradenitis suppurativa (HS), a chronic, debilitating, inflammatory skin disease, share …

Serum metabolomics signatures associated with ankylosing spondylitis and TNF inhibitor therapy

J Ou, M Xiao, Y Huang, L Tu, Z Chen, S Cao… - Frontiers in …, 2021 - frontiersin.org
Ankylosing spondylitis (AS) is a type of spondyloarthropathies, the diagnosis of which is
often delayed. The lack of early diagnosis tools often delays the institution of appropriate …

Smoking in spondyloarthritis: unravelling the complexities

SS Zhao, NJ Goodson, S Robertson, K Gaffney - Rheumatology, 2020 - academic.oup.com
Tobacco smoking is a major threat to health. There is no doubt about the need to promote
and support cessation at every opportunity. Smoking has a clear role in RA, but what …

Mortality rates in patients with ankylosing spondylitis with and without extraarticular manifestations and comorbidities: a retrospective cohort study

E Kelty, M Ognjenovic, WD Raymond… - The Journal of …, 2022 - jrheum.org
Objective. To examine mortality rates in hospitalized patients with ankylosing spondylitis
(AS) and the association of extraarticular manifestations (EAMs) and comorbidities with …

Disease severity in never smokers, ex‐smokers, and current smokers with axial Spondyloarthritis: results from the Scotland registry for ankylosing spondylitis

GT Jones, T Ratz, LE Dean… - Arthritis care & …, 2017 - Wiley Online Library
Objective To examine the relationship between smoking, smoking cessation, and disease
characteristics and quality of life (QoL) in spondyloarthritis. Methods The Scotland Registry …

Cardiovascular risk factors in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: a cross-sectional survey of patients in Western Sweden

AJ Landgren, M Dehlin, L Jacobsson, U Bergsten… - RMD open, 2021 - rmdopen.bmj.com
Objectives We aimed to compare traditional (trad) cardiovascular risk factors (CVRFs)
among patients with gout, psoriatic arthritis (PsA), rheumatoid arthritis (RA) and ankylosing …